Susan Tai
Unknown Affiliation

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

Serum Biomarkers For Hepatocellular Carcinoma (Short Review) Bachtiar, Indra; Utama, Andi; Tai, Susan
Indonesian Journal of Cancer Vol 3, No 2 (2009): Apr - Jun 2009
Publisher : "Dharmais" Cancer Center Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (91.893 KB)

Abstract

Hepatocellular carcinoma (HCC) atau kanker hati adalah salah satu dari kanker yang paling umum dan menjadi penyebab utama kematian di negara-negara Asia. HCC biasanya berkembang pada pasien dengan penyakit hati kronis dan sirosis. Pengamatan HCC pada pasien sirosis biasanya dilakukan menggunakan ?-fetoprotein (AFP) dan ultrasonografi. Akan tetapi, sensitivitas AFP untuk deteksi HCC sangat rendah, sedangkan penggunaan ultrasonografi cukup mahal dan sangat tergantung pada keahlian operator. Hal inilah yang menjadi ide dasar tentang perlunya mencari suatu strategi baru (biomarker baru) dalam mendeteksi HCC secara dini. Biomarker yang ideal harus lebih sensitif, spesifik, noninvasif, murah, dan dapat diterima oleh pasien. Berdasarkan tinjauan literatur yang kami lakukan (2001-2009), dilaporkan beberapa penemuan biomarker baru yang cukup menjanjikan, seperti AFP-L3, des-gamma carboxyprothrombin (DCP), golgi protein 73 (GP73), glypican-3 (GPC3), squamous cell carcinoma antigen (SCCA), transforming growth factor-?1 (TGF?b1), insulin-like growth factor-II (IGF-II), insulin-like growth factor-binding protein-2 (IGFBP-2), human cervical cancer oncogene (HCCR), hepatocyte growth factor (HGF), KL-6 and ?-acid glycoprotein (AAG). Akan tetapi, penggunaannya secara klinis atau uji validasi belum pernah dilaporkan. Beberapa kendala dan keterbatasan yang dilaporkan dalam penemuan biomarker ini antara lain jumlah sampel yang digunakan kurang memadai, metoda analisis yang beragam (heterogenity), terbatas pada wilayah tertentu, predictive analysis biomarker, dan masih sedikitnya studi longitudinal untuk mengevaluasi kemampuan biomarkers dalam mendeteksi penyakit pada taraf preklinik. Uji klinik dan metoda validasi yang tepat saat ini menunggu lahirnya suatu generasi biomarker baru untuk pasien HCC.Kata kunci: Hepatocellular carcinoma (HCC), biomarker, metoda pengujian
Hepatitis B Virus Double Mutations is There any Role in Pathogenesis of Hepatocellular Carcinoma in Young Patients Sulaiman, Andri Sanityoso; Gani, Rino Alvani; Hasan, Irsan; Utama, Andi; Tai, Susan; Christine, Griscalia
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy VOLUME 10, NUMBER 3, December 2009
Publisher : The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (0.036 KB) | DOI: 10.24871/103200996-98

Abstract

Background: The incidence of hepatocellular carcinoma (HCC) below age 40 years old in our institution were relatively high compared with other institutions in Asia. Hepatitis B virus (HBV) basal core promoter (BCP) double mutations correspond with increasing age. The aim of this study was to know if there was any role of HBV double mutations in young HCC patients. Method: A descriptive study was performed on HBV related HCC patients in Cipto Mangunkusumo Hospital in May 2006-November 2008. Patient were recruited consecutively and divided in to two groups, below 40 and above 40 years old. The genotypes were examined by polymerase chain reaction (PCR) method. The alpha feto protein (AFP) values were diagnosed based on ELISA method. The BCP A1762T/G1764A double mutations were examined by direct sequencing. Results: There were 49 HBV related HCC samples consist of 14 (28.5%) samples with age below 40 years old and 35 (71.5%) samples with age above 40 years old. We only found two genotype, genotype B was dominant in patients with HBV related HCC compare to genotype C, 43 (88%) and 6 (12%) respectively. The increasing of AFP level above 400 ng/mL was only found in about half of the samples, 7 (50%) < 40 years old, 19 (54%) > 40 years old. Double mutations of A1762T/G1764A in BCP occurred in 5 (36%) < 40 years old, 15 (43%) > 40 years old. Conclusion: The incidence of HBV related HCC in young patients were relatively high. The proportion of patients with AFP level < 400 ng/mL in patients below 40 years old were higher compared to patients above 40 years.   Keywords: hepatocellular carcinoma, BCP double mutation, HBV genotype